Press Releases Palisade Bio, Inc.

Equities

SNCA

US6963894026

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
6.94 ^USD	-1.70%		-4.80%	-21.58%

May. 07	Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors	CI
May. 01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Palisade Bio Appoints Margery Fischbein to its Board of Directors	May. 07	AQ
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules	May. 02	AQ
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)	May. 01	AQ
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	Apr. 24	AQ
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	Apr. 23	AQ
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 in Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients Stool	Apr. 17	AQ
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool	Apr. 16	AQ
Palisade Bio to Participate in the Virtual Investor Lunch Break Event	Apr. 11	AQ
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™	Apr. 10	AQ
Palisade Bio Announces 1-for-15 Reverse Stock Split	Apr. 03	AQ
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update	Mar. 27	AQ
Palisade Bio to Present at Digestive Disease Week (DDW) 2024	Feb. 15	AQ
Palisade Bio Provides Corporate Update and Reiterates Guidance	Feb. 13	AQ
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members	Feb. 08	AQ
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders	Feb. 08	AQ
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million	Jan. 30	AQ
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress	Jan. 29	AQ
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress	Jan. 09	AQ
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108	Dec. 29	AQ
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108	Dec. 28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Palisade Bio, Inc.

Equities

SNCA

US6963894026

Press Releases

Filters